PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma

Abstract Chimeric antigen receptor (CAR) T‐cell therapy is a promising treatment option for relapsed or refractory (R/R) large B‐cell lymphoma (LBCL). However, only a subset of patients will present long‐term benefit. In this study, we explored the potential of PET‐based radiomics to predict treatme...

Full description

Bibliographic Details
Main Authors:	Marta Ligero, Marc Simó, Cecilia Carpio, Gloria Iacoboni, Maria Balaguer‐Montero, Victor Navarro, Mario Andres Sánchez‐Salinas, Sabela Bobillo, Ana Marín‐Niebla, Josu Iraola‐Truchuelo, Pau Abrisqueta, Roser Sala‐Llonch, Francesc Bosch, Raquel Perez‐Lopez, Pere Barba
Format:	Article
Language:	English
Published:	Wiley 2023-11-01
Series:	eJHaem
Subjects:	CAR T cells DLBCL non‐Hodgkin lymphoma PET progression‐free survival radiomics
Online Access:	https://doi.org/10.1002/jha2.757

Similar Items

Prognostic value of red blood cell distribution width and D‐Dimer in diffuse large B‐cell lymphoma: Systematic review and meta‐analysis
by: Maryam Rahchamani, et al.
Published: (2024-01-01)

BRIDGING TO TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA
by: Christian Gisselbrecht, et al.
Published: (2016-07-01)

B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma
by: Leila Mohammadnezhad, et al.
Published: (2023-05-01)

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
by: Johanna Vets, et al.
Published: (2023-04-01)

The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients
by: Hikmat Abdel-Razeq, et al.
Published: (2021-05-01)

Liquid biopsy in hematological malignancies: current and future applications
by: Donatella Talotta, et al.
Published: (2023-04-01)

Biology and Treatment of Richter Transformation
by: Adalgisa Condoluci, et al.
Published: (2022-03-01)

Primary diffuse large B-cell lymphoma at gastrojejunostomy site: A rare case report
by: Shruthi, et al.
Published: (2023-01-01)

Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review
by: Lali G. Babicheva, et al.
Published: (2023-08-01)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
by: Abdulhaq H, et al.
Published: (2023-07-01)

DIFFUSE LARGE B-CELL LYMPHOMA OF THE HEART
by: Faizah Dwi Tirtasari, et al.
Published: (2022-05-01)

Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)]
by: Luis Villela, et al.
Published: (2022-12-01)

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma
by: Changying Wang, et al.
Published: (2023-03-01)

CD24 is a surrogate for ‘immune‐cold’ phenotype in aggressive large B‐cell lymphoma
by: Morihiro Higashi, et al.
Published: (2022-07-01)

Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature
by: N G GABEEVA, et al.
Published: (2018-07-01)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
by: Xuemei Wu, et al.
Published: (2023-05-01)

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
by: Mark J. Bishton, et al.
Published: (2023-02-01)

Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma - De Novo Occurrence or Transformation
by: Smeeta Gejendra, et al.
Published: (2015-11-01)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)

Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy
by: Mishi Bhushan, et al.
Published: (2021-03-01)

EVT‐701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti‐tumor activity in models of solid cancers
by: Raquel Luna Yolba, et al.
Published: (2021-10-01)

ACUTE RENAL FAILURE DUE TO MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AND TUMORAL CELL INFILTRATION IN A PATIENT WITH MANTLE CELL LYMPHOMA: A CASE REPORT
by: Maria Julia Montoro, et al.
Published: (2014-08-01)

ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
by: Amineh Ghaderi, et al.
Published: (2020-06-01)

Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma
by: Aya Nakaya, et al.
Published: (2016-01-01)

Recurrent fibrin associated diffuse large B-cell lymphoma: A case report
by: Mohebnasab Maedeh, et al.
Published: (2021-09-01)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
by: Anna Nydegger, et al.
Published: (2021-12-01)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
by: Gloria Iacoboni, et al.
Published: (2021-05-01)

The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS
by: Ji-Wei Li, et al.
Published: (2024-01-01)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
by: Yazeed Sawalha
Published: (2021-12-01)

Localised gastrointestinal diffuse large B cell lymphomas; Does surgical approach still exist?
by: Ibrahim Abeer, et al.
Published: (2015-03-01)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
by: Jun Zhu, et al.
Published: (2022-11-01)

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
by: Emma Rabinovich, et al.
Published: (2021-12-01)

CD30 Expression and Its Correlation with Clinicopathologic Features in Indonesian Diffuse Large B-Cell Lymphoma
by: Maria Reynelda Santoso, et al.
Published: (2020-09-01)

The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B‐cell lymphoma
by: Haixiang Pei, et al.
Published: (2022-06-01)

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma
by: Sixia Huang, et al.
Published: (2019-07-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma
by: Mishima Yuko, et al.
Published: (2012-09-01)

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
by: Septiara Putri, et al.
Published: (2022-04-01)

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines
by: Ryohei Kozaki, et al.
Published: (2018-04-01)

Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study
by: Fatemeh Riasi, et al.
Published: (2023-12-01)